Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays

A major impediment to successful use of therapeutic protein drugs is their ability to induce anti-drug antibodies (ADA) that can alter treatment efficacy and safety in a significant number of patients. To this aim, in silico, in vitro, and in vivo tools have been developed to assess sequence and oth...

Descripción completa

Detalles Bibliográficos
Autores principales: Ducret, Axel, Ackaert, Chloé, Bessa, Juliana, Bunce, Campbell, Hickling, Timothy, Jawa, Vibha, Kroenke, Mark A., Lamberth, Kasper, Manin, Anaïs, Penny, Hweixian L., Smith, Noel, Terszowski, Grzegorz, Tourdot, Sophie, Spindeldreher, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8726688/
https://www.ncbi.nlm.nih.gov/pubmed/34923896
http://dx.doi.org/10.1080/19420862.2021.1993522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8726688/
https://www.ncbi.nlm.nih.gov/pubmed/34923896
http://dx.doi.org/10.1080/19420862.2021.1993522

Ejemplares similares